clinical trials, drug development, cancer, FDA

Protesters crash the BIO conference to protest the delayed approval of a breast cancer drug.

The regulatory agency will allow early-stage breast cancer patients to try experimental drugs previously reserved for those with advanced disease.

Drugmakers are teaming up to test the disease-fighting power of combination therapies earlier in the development cycle than ever before.